Fundraising Fox
Artios Pharma
128 employees on LinkedIn · 13 known investors
Find your way into Artios Pharma
Sign up to see every warm intro you have to Artios Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Artios Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
Founders & leadership
Investors · 13
How we know: Andera Partners's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Dementia Discovery Fund's portfolio page · Not right? Tell us
How we know: M Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Novartis Venture Fund's portfolio page · a partner's Signal profile · biopharmadive.com · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · fiercebiotech.com · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · biopharmadive.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: SV Health Investors's portfolio page · funding news · fiercebiotech.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements$115M disclosed across 1 of 2 rounds · 2025
- $115Mseries DNov 2025 · 2 sources
RA Capital Management (lead), SV Health Investors (lead), EQT Life Sciences, Janus Henderson Investors, Novartis Venture Fund, Sofinnova Partners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Artios Pharma do?
- Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
- Who are Artios Pharma's investors?
- Artios Pharma's investors include Andera Partners, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Pfizer Venture Investments, RA Capital, Sofinnova Partners, SV Health Investors and 5 more.
- How much funding has Artios Pharma raised?
- Artios Pharma has disclosed $115M raised across 1 of its 2 known rounds.